Phase II Trial of Vorinostat Plus Tacrolimus and Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant.

Trial Profile

Phase II Trial of Vorinostat Plus Tacrolimus and Mycophenolate to Prevent Graft Versus Host Disease Following Reduced Intensity Conditioning Related Donor Allogeneic Transplant.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Nov 2013

At a glance

  • Drugs Vorinostat (Primary) ; Mycophenolate mofetil; Mycophenolate mofetil; Tacrolimus; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jul 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2012 Primary endpoint 'Acute-graft-versus-host-disease' has been met, as reported at the 54th Annual Meeting of the American Society of Hematology (ASH).
    • 09 Dec 2012 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top